News
Xencor Reports First Quarter 2024 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
“Sangamo continues to progress its
Premier, Inc. to Participate in BofA Securities Healthcare Conference on May 14, 2024
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in a fireside chat at the BofA
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale
ICON releases its ICON Cares 2023 Report
ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2023 Report. This outlines how the company is delivering on its
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of two studies at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
QuidelOrtho Reports First Quarter 2024 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and
Premier, Inc. Announces Cross-Industry Initiative to Improve Diagnosis and Care for Chronic Kidney Disease
Premier, Inc. (NASDAQ: PINC) is excited to announce a strategic partnership with AstraZeneca called Uncover CKD - Care Collective aiming to identify patients with undiagnosed clinical chronic
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
Savara to Present at the Citizens JMP Life Sciences Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the
Inogen Announces First Quarter 2024 Financial Results
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31
STAAR Surgical Reports First Quarter 2024 Results
STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
GenSight Biologics: Annual General Meeting on May 29, 2024
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Acadia Healthcare to Participate in BofA Securities Health Care Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the BofA Securities 2024 Health Care Conference, May 14-16, 2024, in Las Vegas, Nevada.
In
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced
Premier, Inc. Reports Fiscal-Year 2024 Third-Quarter Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2024 third quarter ended March 31, 2024.